Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-label Study of UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

NCT06743503 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06743503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06743503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-label Study of UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 11, 2025
Completion date
July 31, 2030
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma